abstract: In feminising @entity1 , @entity5 can be either secreted by the @entity1 itself or produced by normal Leydig cells in response to paracrine and/or endocrine stimulation by @entity6 . @entity1 patterns include: plasma @entity2 levels > 300 pmol/l on day 3 following an @entity6 injection, reduced plasma @entity3 , and normal plasma @entity6 and gonadotrophin levels. Except for elevated plasma @entity2 levels, opposite results are observed in @entity7 . We report a case of @entity5 -secreting @entity7 mimicking a @entity1 . A 24-year-old Caucasian @entity0 had complained of gynaecomastia for 6 months before admission. Hormonal pattern was typical of @entity1 . A 1.4 cm @entity1 was found in the left @entity4 and confirmed on sonography. Considering the likely diagnosis of @entity1 , the @entity0 was treated by tumourectomy. Surprisingly, pathological examination revealed a pure @entity7 . Perifusion experiments showed that the @entity1 was able to secrete significant amounts of @entity2 . In addition, @entity6 induced a two-fold increase in @entity2 production from perifused @entity1 explants. Immunohistochemistry revealed that the @entity1 was composed of nests of @entity7 cells intermingled with lymphoid infiltrates. @entity1 cells also expressed aromatase, the @entity6 / @entity8 and the Leydig cell marker relaxin-like factor, but were betahCG-negative. These results demonstrate that a pure @entity7 of the @entity4 is able to synthesise and secrete @entity5 . They also illustrate that the body of proof favouring the diagnosis of feminising @entity1 of the @entity4 is not rigorously specific.

title: An @entity5 -producing XXXX responsible for gynaecomastia.

answer: @entity7


abstract: To identify a new regimen to optimize treatment for @entity0 with newly diagnosed @entity2 2 @entity1 (T2DM) by short-term continuous subcutaneous insulin infusion (CSII) alone. Methods. 60 @entity0 with newly diagnosed T2DM were randomized into two groups (n = 30 each) and treated for 2 weeks with CSII alone (CSII group) or with CSII plus @entity4 (CSII + Sig group). The glycemic variability of the @entity0 was measured using a continuous @entity3 monitoring system (CGMS) for the last 72 hours. A standard meal test was performed before and after the interventions, and the levels of glycated albumin, fasting @entity3 , fasting C-peptide, postprandial 2   h blood @entity3 , and postprandial 2   h C-peptide were examined. Results. Compared with the CSII group, the indicators of glycemic variability, such as the mean amplitude of glycemic excursion (MAGE) and the standard deviation of blood @entity3 (SDBG), were decreased significantly in the CSII + Sig group. The changes before and after treatment in the C-peptide reactivity index (  CPI) and the secretory unit of islet in transplantation index (  SUIT) indicated a significant improvement in the CSII + Sig group. Conclusions. Add-on therapy with @entity4 may be an optimized treatment for @entity0 with newly diagnosed T2DM compared with short-term CSII alone.

title: Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with XXXX in @entity0 with Newly Diagnosed @entity1 .

answer: @entity4


abstract: To identify a new regimen to optimize treatment for @entity0 with newly diagnosed @entity2 2 @entity1 (T2DM) by short-term continuous subcutaneous insulin infusion (CSII) alone. Methods. 60 @entity0 with newly diagnosed T2DM were randomized into two groups (n = 30 each) and treated for 2 weeks with CSII alone (CSII group) or with CSII plus @entity4 (CSII + Sig group). The glycemic variability of the @entity0 was measured using a continuous @entity3 monitoring system (CGMS) for the last 72 hours. A standard meal test was performed before and after the interventions, and the levels of glycated albumin, fasting @entity3 , fasting C-peptide, postprandial 2   h blood @entity3 , and postprandial 2   h C-peptide were examined. Results. Compared with the CSII group, the indicators of glycemic variability, such as the mean amplitude of glycemic excursion (MAGE) and the standard deviation of blood @entity3 (SDBG), were decreased significantly in the CSII + Sig group. The changes before and after treatment in the C-peptide reactivity index (  CPI) and the secretory unit of islet in transplantation index (  SUIT) indicated a significant improvement in the CSII + Sig group. Conclusions. Add-on therapy with @entity4 may be an optimized treatment for @entity0 with newly diagnosed T2DM compared with short-term CSII alone.

title: Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with @entity4 in @entity0 with Newly Diagnosed XXXX .

answer: @entity1


abstract: To identify a new regimen to optimize treatment for @entity0 with newly diagnosed @entity2 2 @entity1 (T2DM) by short-term continuous subcutaneous insulin infusion (CSII) alone. Methods. 60 @entity0 with newly diagnosed T2DM were randomized into two groups (n = 30 each) and treated for 2 weeks with CSII alone (CSII group) or with CSII plus @entity4 (CSII + Sig group). The glycemic variability of the @entity0 was measured using a continuous @entity3 monitoring system (CGMS) for the last 72 hours. A standard meal test was performed before and after the interventions, and the levels of glycated albumin, fasting @entity3 , fasting C-peptide, postprandial 2   h blood @entity3 , and postprandial 2   h C-peptide were examined. Results. Compared with the CSII group, the indicators of glycemic variability, such as the mean amplitude of glycemic excursion (MAGE) and the standard deviation of blood @entity3 (SDBG), were decreased significantly in the CSII + Sig group. The changes before and after treatment in the C-peptide reactivity index (  CPI) and the secretory unit of islet in transplantation index (  SUIT) indicated a significant improvement in the CSII + Sig group. Conclusions. Add-on therapy with @entity4 may be an optimized treatment for @entity0 with newly diagnosed T2DM compared with short-term CSII alone.

title: Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with @entity4 in XXXX with Newly Diagnosed @entity1 .

answer: @entity0


abstract: Streptokinase (SK) interacts with @entity0 plasminogen (Pg) or @entity2 (Pm) with formation of Pg-SK or Pm-SK complex. Pm-SK complex manifests a fibrinolytic, amidolytic and Pg activator activity. SK in complex with Pm isn't stable and so capable to be hydrolysed rapidly. We investigated a correlation between molecular form of SK and catalytic properties of equimolar Pm-SK complex during preincubation at 20 degrees C. It was found out that amidolytic activity of Pm-SK complex was not changing for 5 hours and decreased to the initial Pm value after 24 hours. During this time @entity3 ( @entity3 ) has any effect on amidolytic activity of the complex. Fibrinolytic activity of Pm-SK complex makes up 20% of the initial Pm value and wasn't changing within the investigated period. Pg activator activity was decreasing rapidly to 30-40% of the initial one within few minutes from the moment of Pm-SK complex formation. It was 10-20% of that initial after 24 hours. The decrease in Pg activator activity of Pm-SK complex correlated with the initial very rapid conversion of 47 kDa SK to 36 kDa SK within few minutes and following more slow conversion of SK in 31, 25 and 15 kDa fragments after 5 hours. @entity3 didn't influence on the Pg activator activity of Pm-SK complex but eliminated its fibrinolytic activity completely. It was supposed that @entity3 inhibited fibrinolytic activity of Pm-SK complex similarly to @entity1 by preventing Pm-SK complex binding to fibrin polymer.

title: [Degradation of streptokinase and the catalytic properties of the XXXX -streptokinase complex].

answer: @entity2


abstract: BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) has established popularity as a weight loss procedure based on its success. However, LSG's effect on @entity2 ( @entity2 ) is unknown. OBJECTIVES: To analyze the incidence of @entity2 after LSG and to compare the results in @entity0 with preexisting and de novo @entity2 . SETTING: Tertiary Medical center. METHODS: The authors performed a retrospective review of primary LSG from 2005 to 2013 and compared @entity0 with pre-existing and de novo @entity2 who underwent LSG. RESULTS: A total of 919 @entity0 underwent LSG. @entity2 was present in 38 (4%) of the LSG cohort. We identified 2 groups: Group A consisted of 25 (3%) @entity0 with de novo @entity2 , and Group B consisted of 13 (1%) @entity0 with pre-existing @entity2 . Diagnosis of @entity2 in both groups was determined by symptoms and history of proton pump inhibitor (PPI) treatment, upper @entity1 , esophagogastroduodenoscopy, and pH manometry. In Group A, 1 (4%) @entity0 was managed with over-the-counter drugs, 17 (68%) @entity0 were treated with low-dose PPI, 6 (24%) @entity0 were treated with high-dose PPI, and 1 (4%) @entity0 was lost to follow-up. Group B consisted of 9 (69%) @entity0 treated with low-dose PPI and 4 (31%) @entity0 treated with high-dose PPI. Medical treatment failed in 4 @entity0 (10.5%) who subsequently required conversion to laparoscopic Roux-en-Y gastric bypass (LRYGB). In Group A, 1 @entity0 (4%) required LRYGB, and in Group B, 3 @entity0 (23%) required LRYGB. The outcome of conversion for Group A was incomplete resolution of symptoms in the 1 @entity0 , whereas in Group B, all 3 @entity0 (100%) had complete resolution of @entity2 symptoms after LRYGB. CONCLUSIONS: In this study, 3% of @entity0 developed de novo @entity2 , but most responded to either low- or high-dose PPI, with 4% requiring conversion to LRYGB.

title: Impact of sleeve gastrectomy on XXXX in a morbidly obese population undergoing bariatric surgery.

answer: @entity2


abstract: After @entity2 -related phase I dose-finding trials are completed in Western countries, further phase I trials are often conducted to determine recommended doses (RDS) for Japanese @entity1 . This may be due to concerns about possible differences in treatment tolerability between Caucasians and Japanese. In most of these, a conventional '3 +3' cohort study design is used in making dose escalation decisions, possibly due to its relatively easy implementation. Since its proposal by O'Quigleybiet al. (1990; Biometrics, 46:33-48), the continual reassessment method (CRM) has been used increasingly in @entity2 -related phase I dose-finding studies as an alternative to '3 +3' designs. One of the principal advantages of applying a Bayesian CRM may be the utilization of all available prior information to estimate RDS through prior distributions that are assumed for model parameters representing the dose-toxicity relationship. In this paper, we present an application of the Bayesian CRM to a phase I dose-finding study in Japanese @entity1 with @entity0 using an informative prior elicited from clinical investigators. In some settings, it may be appropriate to use an informative prior that reflects the accurate and comprehensive previous knowledge of clinical investigators. On the other hand, for a model-based Bayesian outcome-adaptive clinical trial, it is necessary to establish sufficiently vague priors so that accumulating data dominate decisions as the amount of observed data increases. Thus, we retrospectively investigated the relative strength of the prior using a recently proposed method to compute a prior effective sample size.

title: Application of the continual reassessment method to a phase I dose-finding trial in Japanese XXXX : East meets West.

answer: @entity1


abstract: A study was performed on eight subjects with @entity2 to assess the relation between gonadal hormones and opioid inhibition of gonadotropin secretion through comparison of their gonadotropin response to @entity3 ( @entity5 ) (0.3 mg/kg; 1/3 bolus iv. at time 0 and 2/3 iv. for 120 min) before and after @entity4 (TP) 100 mg/day im. for 5 days. Under basal conditions, NAL failed to induce a significant change in LH levels. After TP, however, despite unchanged basal LH levels (mean +/- S.E.M.: 27.0 +/- 3.4 vs 21.2 +/- 3.21 microU/ml), LH significantly increased in response to NAL. FSH did not respond to NAL either before or after TP administration, though FSH levels were significantly reduced by TP. These findings suggest that in @entity0 , as in animals, gonadal hormones regulate opioid inhibition of LH secretion. The negative feedback of @entity1 and its ability to activate opioid inhibiting tone may be dissociated, in keeping with the view that gonadal hormones control gonadotropin secretion through the activation of distinct, albeit concomitant, mechanisms.

title: Effect of @entity3 on gonadotropin secretion before and after XXXX in @entity2 .

answer: @entity1


abstract: A study was performed on eight subjects with @entity2 to assess the relation between gonadal hormones and opioid inhibition of gonadotropin secretion through comparison of their gonadotropin response to @entity3 ( @entity5 ) (0.3 mg/kg; 1/3 bolus iv. at time 0 and 2/3 iv. for 120 min) before and after @entity4 (TP) 100 mg/day im. for 5 days. Under basal conditions, NAL failed to induce a significant change in LH levels. After TP, however, despite unchanged basal LH levels (mean +/- S.E.M.: 27.0 +/- 3.4 vs 21.2 +/- 3.21 microU/ml), LH significantly increased in response to NAL. FSH did not respond to NAL either before or after TP administration, though FSH levels were significantly reduced by TP. These findings suggest that in @entity0 , as in animals, gonadal hormones regulate opioid inhibition of LH secretion. The negative feedback of @entity1 and its ability to activate opioid inhibiting tone may be dissociated, in keeping with the view that gonadal hormones control gonadotropin secretion through the activation of distinct, albeit concomitant, mechanisms.

title: Effect of XXXX on gonadotropin secretion before and after @entity1 in @entity2 .

answer: @entity3


abstract: A study was performed on eight subjects with @entity2 to assess the relation between gonadal hormones and opioid inhibition of gonadotropin secretion through comparison of their gonadotropin response to @entity3 ( @entity5 ) (0.3 mg/kg; 1/3 bolus iv. at time 0 and 2/3 iv. for 120 min) before and after @entity4 (TP) 100 mg/day im. for 5 days. Under basal conditions, NAL failed to induce a significant change in LH levels. After TP, however, despite unchanged basal LH levels (mean +/- S.E.M.: 27.0 +/- 3.4 vs 21.2 +/- 3.21 microU/ml), LH significantly increased in response to NAL. FSH did not respond to NAL either before or after TP administration, though FSH levels were significantly reduced by TP. These findings suggest that in @entity0 , as in animals, gonadal hormones regulate opioid inhibition of LH secretion. The negative feedback of @entity1 and its ability to activate opioid inhibiting tone may be dissociated, in keeping with the view that gonadal hormones control gonadotropin secretion through the activation of distinct, albeit concomitant, mechanisms.

title: Effect of @entity3 on gonadotropin secretion before and after @entity1 in XXXX .

answer: @entity2


abstract: In several species, there is a strong correlation between indicators of @entity3 ( @entity3 ) and thromboelastometry results. The @entity1 has a reliable, temporary, @entity4 in response to @entity2 infusion. Our objective was to evaluate the effects of an in-vivo increase in circulating @entity3 on thromboelastometry results in an @entity1 model of transient @entity4 . Six healthy research @entity1 had whole blood thromboelastometry with contact activator and tissue factor initiation after recalcification of citrated samples. Additional samples were frozen for thrombin-antithrombin (TAT). Complete blood count biochemical analysis, fibrinogen, activated partial thromboplastin time (aPTT), and prothrombin time (PT) were performed. Additional samples were taken at 5 min and 2 h after @entity2 infusion. Thromboelastometry was performed separately on four @entity1 not receiving @entity2 with the samples divided and spiked with @entity2 ex vivo. Red cell count (P<0.001) and hematocrit (P<0.001) were significantly higher at 5 min after @entity2 compared with baseline and 2 h. There was no change in platelet count, fibrinogen, PT, aPTT, or TAT at any time point. Both ex-tem and in-tem parameters were hypocoagulable at 5 min after @entity2 compared to baseline and 2 h. There was no effect of @entity2 in the ex-vivo spiking studies on any of the thromboelastometry parameters. Whole blood thromboelastometry results were hypocoagulable in this @entity1 model of in-vivo transient @entity4 only during the polycythemic phase. All other coagulation parameters were unchanged. In the absence of other indicators of hypocoagulability, this may point to an artifact of thromboelastometry. Alternatively, the data may reflect true in-vivo hypocoagulability in @entity0 with increased circulating @entity3 .

title: In-vitro hypocoagulability on whole blood thromboelastometry associated with in-vivo expansion of XXXX in an @entity1 model.

answer: @entity3


abstract: In several species, there is a strong correlation between indicators of @entity3 ( @entity3 ) and thromboelastometry results. The @entity1 has a reliable, temporary, @entity4 in response to @entity2 infusion. Our objective was to evaluate the effects of an in-vivo increase in circulating @entity3 on thromboelastometry results in an @entity1 model of transient @entity4 . Six healthy research @entity1 had whole blood thromboelastometry with contact activator and tissue factor initiation after recalcification of citrated samples. Additional samples were frozen for thrombin-antithrombin (TAT). Complete blood count biochemical analysis, fibrinogen, activated partial thromboplastin time (aPTT), and prothrombin time (PT) were performed. Additional samples were taken at 5 min and 2 h after @entity2 infusion. Thromboelastometry was performed separately on four @entity1 not receiving @entity2 with the samples divided and spiked with @entity2 ex vivo. Red cell count (P<0.001) and hematocrit (P<0.001) were significantly higher at 5 min after @entity2 compared with baseline and 2 h. There was no change in platelet count, fibrinogen, PT, aPTT, or TAT at any time point. Both ex-tem and in-tem parameters were hypocoagulable at 5 min after @entity2 compared to baseline and 2 h. There was no effect of @entity2 in the ex-vivo spiking studies on any of the thromboelastometry parameters. Whole blood thromboelastometry results were hypocoagulable in this @entity1 model of in-vivo transient @entity4 only during the polycythemic phase. All other coagulation parameters were unchanged. In the absence of other indicators of hypocoagulability, this may point to an artifact of thromboelastometry. Alternatively, the data may reflect true in-vivo hypocoagulability in @entity0 with increased circulating @entity3 .

title: In-vitro hypocoagulability on whole blood thromboelastometry associated with in-vivo expansion of @entity3 in an XXXX model.

answer: @entity1


abstract: UNASSIGNED: OBJECTIVE The objective of this study was to compare fractionation schemes and outcomes of @entity0 with @entity2 ( @entity2 ) treated in institutional prospective spinal stereotactic radiosurgery (SSRS) trials who did not previously undergo radiation treatment at the site of the SSRS. METHODS @entity0 enrolled in 2 separate institutional prospective protocols and treated with SSRS between 2002 and 2011 were included. A secondary analysis was performed on @entity0 with previously nonirradiated @entity2 spinal metastases treated with either single-fraction (SF) or multifraction (MF) SSRS. RESULTS SSRS was performed in 47 spinal sites on 43 @entity0 . The median age of the @entity0 was 62 years (range 38-75 years). The most common histological subtype was clear cell (n = 30). Fifteen sites underwent surgery prior to the SSRS, with laminectomy the most common procedure performed (n = 10). All SF SSRS was delivered to a dose of 24 Gy (n = 21) while MF regiments were either 27 Gy in 3 fractions (n = 20) or 30 Gy in 5 fractions (n = 6). The median overall survival duration for the entire cohort was 22.8 months. The median local control (LC) for the entire cohort was 80.6 months with 1-year and 2-year actuarial LC rates of 82% and 68%, respectively. Single-fraction SSRS correlated with improved 1- and 2-year actuarial LC relative to MF SSRS (95% vs 71% and 86% vs 55%, respectively; p = 0.009). On competing risk analysis, SF SSRS showed superior LC to MF SSRS (subhazard ratio [SHR] 6.57, p = 0.014). On multivariate analysis for LC with @entity1 volume (p = 0.272), number of treated levels (p = 0.819), gross @entity1 volume (GTV) coverage (p = 0.225), and GTV minimum point dose (p = 0.97) as covariates, MF SSRS remained inferior to SF SSRS (SHR 5.26, p = 0.033) CONCLUSIONS SSRS offers durable LC for spinal metastases from @entity2 . Single-fraction SSRS is associated with improved LC over MF SSRS for previously nonirradiated @entity2 spinal metastases.

title: Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from XXXX : secondary analysis of Phase I/II trials.

answer: @entity2


abstract: UNASSIGNED: Introduction @entity0 with mutations in @entity3 can have @entity2 ( @entity2 ), @entity4 ( @entity4 ), or @entity2 - @entity4 . The goals were to establish whether cortical hyperexcitability occurs in @entity3 @entity0 with different clinical presentations. Methods Cortical thresholds and silent periods were measured in thenar muscles in 19 @entity0 with @entity3 expansions and 21 healthy controls using @entity5 ( @entity5 ). El Escorial and Rascovsky criteria were used to diagnose @entity2 and @entity4 . Fourteen @entity0 with @entity3 expansions were re-tested 6 months later. Correlations with finger-tapping speed, timed peg test, the @entity2 functional rating scale, and @entity1 Rating Scale were examined. Results Most @entity0 with @entity3 expansions had normal or low cortical thresholds. Among them, @entity2 @entity0 had the lowest thresholds and significantly shorter silent periods. Thresholds correlated with timed peg-test scores. @entity5 did not correlate with the @entity1 Rating Scale. Conclusion @entity5 measures of cortical excitability may serve as non-invasive biomarkers of @entity2 disease activity. This article is protected by copyright. All rights reserved.

title: Cortical hyperexcitability in @entity0 with XXXX mutations: relationship to phenotype.

answer: @entity3


abstract: UNASSIGNED: Introduction @entity0 with mutations in @entity3 can have @entity2 ( @entity2 ), @entity4 ( @entity4 ), or @entity2 - @entity4 . The goals were to establish whether cortical hyperexcitability occurs in @entity3 @entity0 with different clinical presentations. Methods Cortical thresholds and silent periods were measured in thenar muscles in 19 @entity0 with @entity3 expansions and 21 healthy controls using @entity5 ( @entity5 ). El Escorial and Rascovsky criteria were used to diagnose @entity2 and @entity4 . Fourteen @entity0 with @entity3 expansions were re-tested 6 months later. Correlations with finger-tapping speed, timed peg test, the @entity2 functional rating scale, and @entity1 Rating Scale were examined. Results Most @entity0 with @entity3 expansions had normal or low cortical thresholds. Among them, @entity2 @entity0 had the lowest thresholds and significantly shorter silent periods. Thresholds correlated with timed peg-test scores. @entity5 did not correlate with the @entity1 Rating Scale. Conclusion @entity5 measures of cortical excitability may serve as non-invasive biomarkers of @entity2 disease activity. This article is protected by copyright. All rights reserved.

title: Cortical hyperexcitability in XXXX with @entity3 mutations: relationship to phenotype.

answer: @entity0


abstract: UNASSIGNED: Neoadjuvant chemotherapy (NAC) is intensively used for the treatment of primary @entity0 . In our previous studies, we reported that clinical @entity2 response to NAC is associated with the change of multidrug resistance (MDR) gene expression in @entity2 after chemotherapy. In this study we performed a combined analysis of MDR gene locus deletions in @entity2 DNA, MDR gene expression and clinical response to NAC in 73 BC @entity1 . Copy number variations (CNVs) in biopsy specimens were tested using high-density microarray platform CytoScanTM @entity4 Array (Affymetrix, USA). 75%-100% @entity1 having deletions of MDR gene loci demonstrated the down-regulation of MDR gene expression. Expression of MDR genes was 2-8 times lower in @entity1 with deletion than in @entity1 having no deletion only in post-NAC @entity2 samples but not in @entity2 tissue before chemotherapy. All @entity1 with deletions of @entity3 ABCB 3 @entity9 gene loci - 7q21.1, 6p21.32, 3q27 correspondingly, and most @entity1 having deletions in @entity7 (16p13.1), @entity5 (10q24), @entity8 (21q22.3), @entity6 (4q22.1), responded favorably to NAC. The analysis of all CNVs, including both amplification and deletion showed that the frequency of 13q14.2 deletion was 85% among @entity1 @entity2 with the deletion at least in one MDR gene locus versus 9% in @entity1 with no deletions. Differences in the frequency of 13q14.2 deletions between the two groups were statistically significant (p = 2.03 *10-11, Fisher test, Bonferroni-adjusted p = 1.73 * 10-8). In conclusion, our study for the first time demonstrates that deletion MDR gene loci can be used as predictive marker for @entity2 response to NAC.

title: Deletions of multidrug resistance gene loci in XXXX leads to the down-regulation of its expression and predict @entity2 response to neoadjuvant chemotherapy.

answer: @entity0


abstract: UNASSIGNED: Neoadjuvant chemotherapy (NAC) is intensively used for the treatment of primary @entity0 . In our previous studies, we reported that clinical @entity2 response to NAC is associated with the change of multidrug resistance (MDR) gene expression in @entity2 after chemotherapy. In this study we performed a combined analysis of MDR gene locus deletions in @entity2 DNA, MDR gene expression and clinical response to NAC in 73 BC @entity1 . Copy number variations (CNVs) in biopsy specimens were tested using high-density microarray platform CytoScanTM @entity4 Array (Affymetrix, USA). 75%-100% @entity1 having deletions of MDR gene loci demonstrated the down-regulation of MDR gene expression. Expression of MDR genes was 2-8 times lower in @entity1 with deletion than in @entity1 having no deletion only in post-NAC @entity2 samples but not in @entity2 tissue before chemotherapy. All @entity1 with deletions of @entity3 ABCB 3 @entity9 gene loci - 7q21.1, 6p21.32, 3q27 correspondingly, and most @entity1 having deletions in @entity7 (16p13.1), @entity5 (10q24), @entity8 (21q22.3), @entity6 (4q22.1), responded favorably to NAC. The analysis of all CNVs, including both amplification and deletion showed that the frequency of 13q14.2 deletion was 85% among @entity1 @entity2 with the deletion at least in one MDR gene locus versus 9% in @entity1 with no deletions. Differences in the frequency of 13q14.2 deletions between the two groups were statistically significant (p = 2.03 *10-11, Fisher test, Bonferroni-adjusted p = 1.73 * 10-8). In conclusion, our study for the first time demonstrates that deletion MDR gene loci can be used as predictive marker for @entity2 response to NAC.

title: Deletions of multidrug resistance gene loci in @entity0 leads to the down-regulation of its expression and predict XXXX response to neoadjuvant chemotherapy.

answer: @entity2


abstract: UNASSIGNED: @entity5 is an @entity1 in which inappropriate stimulation of the thyroid gland results in unregulated secretion of thyroid hormones resulting in @entity3 . @entity5 is the most common cause of @entity5 during pregnancy. Treatment options for @entity5 include @entity9 therapy, partial or total thyroidectomy, and radioactive @entity4 . In this article, we review guideline recommendations for @entity5 treatment in @entity0 of reproductive age including the recent guideline from the American College of Obstetricians and Gynecologists. Controversy regarding appropriate @entity9 therapy before, during, and after pregnancy is reviewed. Surgical and radioactive @entity4 therapy considerations in this @entity0 population are also reviewed. In @entity0 who may find themselves pregnant during therapy or develop @entity5 during their pregnancy, consideration should be given to the most appropriate treatment course for the mother and fetus. @entity9 therapy should be used with either @entity8 or @entity7 at appropriate doses that target the upper range of normal to slightly @entity3 to avoid creating @entity2 in the fetus. Consideration should also be given to the adverse effects of @entity9 , such as @entity6 and hepatotoxicity, with appropriate @entity0 consultation regarding signs and symptoms. Individuals who wish to breastfeed their @entity0 while taking @entity9 should receive the lowest effective dose. Surgery should be reserved for extreme cases and limited to the second trimester, if possible. Radioactive @entity4 therapy may be used in nonpregnant individuals, with limited harm to future fertility. Radioactive @entity4 therapy should be withheld in pregnant @entity0 and those who are actively breastfeeding. Clinicians should keep abreast of developments in clinical trials and evidence-based recommendations regarding @entity5 in reproductive-age @entity0 for any changes in evidence-based practice.

title: Graves' Disease Pharmacotherapy in XXXX of Reproductive Age.

answer: @entity0


abstract: One hundred and sixty-three @entity0 subjected to three different types of thoracic operation were allocated randomly either to balanced intravenous anaesthesia including i.v. opiates with post-operative intramuscular opiates (intramuscular group) or to balanced intravenous anaesthesia without i.v. opiates but with high thoracic epidural regional block during the operation as well as epidural @entity6 post-operatively (epidural group). Post-operative @entity6 in either group was given only at the request of the @entity0 and as frequently as needed to obtain satisfactory @entity2 relief. @entity0 in the epidural group were given @entity6 exclusively by epidural injection. @entity0 in the epidural group required significantly less @entity6 for effective @entity2 relief (29 mg (sd = 10) over a period of 3 days compared to 52 mg (sd = 27) in the intramuscular group. Significantly fewer @entity4 in the epidural group were observed (9 atelectases in 83 @entity0 in the epidural group compared to 24 atelectases in 80 @entity0 in the intramuscular group). Only one @entity0 developed @entity1 (intramuscular group). Although the epidural catheter was inserted at the T3-T4 level, no signs of @entity3 were found; on the contrary, respiration in the epidural group was significantly better than the intramuscular group. None of the @entity0 , in either @entity5 group, needed to be ventilated post-operatively.

title: Post-operative @entity5 by epidural versus intramuscular XXXX after thoracotomy. Part II.

answer: @entity6


abstract: One hundred and sixty-three @entity0 subjected to three different types of thoracic operation were allocated randomly either to balanced intravenous anaesthesia including i.v. opiates with post-operative intramuscular opiates (intramuscular group) or to balanced intravenous anaesthesia without i.v. opiates but with high thoracic epidural regional block during the operation as well as epidural @entity6 post-operatively (epidural group). Post-operative @entity6 in either group was given only at the request of the @entity0 and as frequently as needed to obtain satisfactory @entity2 relief. @entity0 in the epidural group were given @entity6 exclusively by epidural injection. @entity0 in the epidural group required significantly less @entity6 for effective @entity2 relief (29 mg (sd = 10) over a period of 3 days compared to 52 mg (sd = 27) in the intramuscular group. Significantly fewer @entity4 in the epidural group were observed (9 atelectases in 83 @entity0 in the epidural group compared to 24 atelectases in 80 @entity0 in the intramuscular group). Only one @entity0 developed @entity1 (intramuscular group). Although the epidural catheter was inserted at the T3-T4 level, no signs of @entity3 were found; on the contrary, respiration in the epidural group was significantly better than the intramuscular group. None of the @entity0 , in either @entity5 group, needed to be ventilated post-operatively.

title: Post-operative XXXX by epidural versus intramuscular @entity6 after thoracotomy. Part II.

answer: @entity5


abstract: BACKGROUND: The aim of this study was to evaluate the time course of recovery from cerebral vulnerability, using microdialysis (MD) technique and cerebral vascular autoregulation measurement, to clarify the appropriate timing of subsequent major surgical procedures, and to minimize the possibility of secondary @entity6 in @entity0 with severe @entity1 (STBI). METHODS: In 3,470 MD samples of 25 @entity0 with STBI, cerebral extracellular biomarkers ( @entity2 , @entity5 , @entity8 , @entity4 , and @entity7 ) were measured. In addition, to estimate cerebral vascular autoregulaton, the pressure reactivity index (PRx) was calculated with @entity3 ( @entity3 ) and mean arterial pressure. The data with @entity3 , cerebral perfusion pressure (CPP), and PRx were collected hourly for 7 days after injury and they were compared with MD biomarkers daily. RESULTS: During the study period, the average @entity3 and CPP remained stable and were within the threshold of STBI treatment guidelines. After injury, the extracellular @entity2 concentration decreased, and the levels of @entity4 , @entity7 , and @entity5 / @entity8 ratio (LPR), which indicate @entity9 and @entity1 , increased. On the fourth day after injury, the extracellular @entity2 concentration improved, and the value of LPR decreased. The average PRx decreased daily and became negative on the fifth day after injury. CONCLUSION: Our results indicated that cerebral vascular autoregulation would recover on the fourth day after STBI, and cerebral perfusion might be increased by recovery of autoregulation. Thus, subsequent nonemergent surgery should be performed at least 4 days after STBI to prevent secondary @entity6 . In addition, we should keep in mind that the cerebral vulnerability might persist for 4 days after suffering STBI.

title: Time course of recovery from cerebral vulnerability after severe XXXX : a microdialysis study.

answer: @entity1


abstract: UNASSIGNED: Inappropriate secretion of TSH was first described in 1960 in a @entity0 with evidence of @entity4 and expanded sella on imaging. It was later found that a type of pituitary adenoma that secretes TSH (thyrotropinoma) was the underlying cause. The objective of the present review article is to summarize data on the epidemiology, pathogenesis, diagnosis, and management of thyrotropinomas. The prevalence of thyrotropinomas is lower than that of other @entity3 . Early diagnosis is now possible thanks to the availability of magnetic resonance imaging and sensitive laboratory assays. As a corollary, many @entity0 now present earlier in the course of their disease and have smaller @entity1 at the time of diagnosis. Treatment also has evolved over time. Transsphenoidal surgery is still considered definitive therapy. Meanwhile, radiation therapy, including radiosurgery, is effective in achieving @entity1 control in the majority of @entity0 . In the past, radiation therapy was used as second line treatment in @entity0 with residual or recurrent @entity1 after surgery. However, the availability of @entity5 analogs, which can lead to normalization of thyroid function as well as shrink these @entity1 , has led to an increase in the role of medical therapy in @entity0 who are not in remission after pituitary surgery. In addition, @entity2 agonists have shown some efficacy in the management of these @entity1 . Better understanding of the molecular pathogenesis of thyrotropinomas may lead to rationally designed therapies for @entity0 with thyrotropinomas.

title: Thyrotropin-secreting XXXX : epidemiology, diagnosis, and management.

answer: @entity3


abstract: Development of a hospital prospective payment system (PPS) for Medicare @entity0 based on diagnosis related groups (DRGs) should generate renewed interest in acute care utilization by @entity2 @entity0 . Within the @entity4 , these @entity0 are classified as DRG 14--specific @entity3 except transient @entity1 attacks. Hospitals are paid a relatively fixed rate for each Medicare @entity0 within this category. In order to investigate patterns of inpatient care for this DRG, hospital utilization patterns in four United States metropolitan areas with a variety of acute and long-term care utilization characteristics were compared. The study involved a total of 4,593 discharges in DRG 14. Hospital discharge and admission rates and mean stays of the four sample populations were evaluated. Data demonstrated that discharge and admission rates of the four areas in this DRG were similar. However, the results also indicated that mean stays for DRG 14 varied by over 100%. These differences could not be explained by differences in age level and payor status of sample populations. Some variations appeared to be related to limitations in the availability of nursing home beds for posthospital care @entity2 @entity0 . These results suggest that efforts to improve the efficiency of hospital care for @entity2 @entity0 under DRGs must increasingly focus on long-term care services.

title: XXXX hospitalization under prospective payments: analysis of diagnosis related group 14.

answer: @entity2


abstract: BACKGROUND: Botulinum toxin type A has been used for treating the @entity1 of the masseter muscles and its cosmetic effects. Ultrasound is increasingly used in dermatology, along with the guidance of mini-invasive procedures. AIMS: To evaluate the role of ultrasound for guiding the application of Botulinum A toxin in @entity0 with cosmetic alterations due to @entity2 , correlate the clinical landmarks with the ultrasound findings, and study the effect on the symptoms, cosmetics, and quality of life. @entity0 /METHODS: Twenty individuals with @entity2 and cosmetic alterations underwent an ultrasound-guided injection of Botulinum toxin type A in each masseter muscle. Clinical and ultrasound marking of the procedure was compared. Clinical and sonographic evaluation was performed at the time of injection and 3 months later. Ten normal individuals underwent ultrasound of the masseter muscles as a control group. RESULTS: Up to 65% of individuals showed anatomical variants of the salivary glands. The method for clinically marking the skin showed a frequently erroneous location of the anterior point (up to 40% of cases) that was proven by ultrasound to be out of the muscle. In 20% of cases, ultrasound showed that the needle should be longer to enter the muscle. After injection, most of the @entity0 demonstrated a decrease of the symptoms and cosmetic and quality of life improvements. CONCLUSIONS: Ultrasound can be a potent tool for guiding the injection of Botulinum toxin into the masseter muscles. It may contribute to a more personalized procedure, better cosmetic results, and help to avoid potential complications.

title: Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating XXXX and its cosmetic effects.

answer: @entity2


abstract: UNASSIGNED: @entity0 ( @entity0 ) is an aggressive subtype of @entity0 with a poor prognosis, which lacks effective targeted therapies. There is an urgent need to better understand the underlying molecular mechanisms of @entity0 @entity2 and identify novel, efficient targets for therapeutic intervention. METHODS: miRNA qRT-PCR was used to determine the expression of @entity5 in cell lines. The @entity5 overexpression effects in @entity0 cell lines were investigated using assays of colony formation, cell cycle and apoptosis. Immunoblotting was performed to determine the expression of the @entity5 target protein, and luciferase assays were performed to confirm the target of @entity5 action. RESULTS: @entity5 expression was significantly suppressed in @entity0 cell lines and tissues samples. Overexpression of @entity5 significantly suppressed cell proliferation of two @entity0 cell lines when compared to control miRNA-expressing cells. A significant decrease in the S-phase of the cell cycle was observed following @entity5 overexpression, accompanied by induction of apoptosis in @entity0 cells. @entity4 ( @entity4 ) was identified as a target of @entity5 action. @entity5 overexpression significantly suppressed the luciferase activity of reporter plasmid containing the 3'UTR of @entity4 and protein expression levels of @entity4 in @entity0 cells. The effects of @entity5 overexpression on @entity0 cell growth were reversed by @entity4 overexpression. @entity5 expression sensitized @entity0 cells to @entity3 treatment. CONCLUSION: Our results demonstrate a novel @entity1 suppressor role for @entity5 in triple-negative @entity0 cell lines, identify @entity4 as its target of action, and demonstrate a potential role for @entity5 in sensitizing @entity0 cells to @entity3 .

title: @entity1 suppressor role of microRNA-1296 in triple-negative XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity0 ( @entity0 ) is an aggressive subtype of @entity0 with a poor prognosis, which lacks effective targeted therapies. There is an urgent need to better understand the underlying molecular mechanisms of @entity0 @entity2 and identify novel, efficient targets for therapeutic intervention. METHODS: miRNA qRT-PCR was used to determine the expression of @entity5 in cell lines. The @entity5 overexpression effects in @entity0 cell lines were investigated using assays of colony formation, cell cycle and apoptosis. Immunoblotting was performed to determine the expression of the @entity5 target protein, and luciferase assays were performed to confirm the target of @entity5 action. RESULTS: @entity5 expression was significantly suppressed in @entity0 cell lines and tissues samples. Overexpression of @entity5 significantly suppressed cell proliferation of two @entity0 cell lines when compared to control miRNA-expressing cells. A significant decrease in the S-phase of the cell cycle was observed following @entity5 overexpression, accompanied by induction of apoptosis in @entity0 cells. @entity4 ( @entity4 ) was identified as a target of @entity5 action. @entity5 overexpression significantly suppressed the luciferase activity of reporter plasmid containing the 3'UTR of @entity4 and protein expression levels of @entity4 in @entity0 cells. The effects of @entity5 overexpression on @entity0 cell growth were reversed by @entity4 overexpression. @entity5 expression sensitized @entity0 cells to @entity3 treatment. CONCLUSION: Our results demonstrate a novel @entity1 suppressor role for @entity5 in triple-negative @entity0 cell lines, identify @entity4 as its target of action, and demonstrate a potential role for @entity5 in sensitizing @entity0 cells to @entity3 .

title: XXXX suppressor role of microRNA-1296 in triple-negative @entity0 .

answer: @entity1


abstract: UNASSIGNED: In the last years, rituximab (RTX) and agonists of the @entity5 ( @entity5 ) eltrombopag and romiplostim have provided new treatment options in persistent and chronic @entity4 ( @entity4 ). Here, we analyzed the changes in therapeutic choices over time and their impact on clinical outcomes in a cohort of 557 @entity4 outpatients followed at the "L. and A. Ser  gnoli" Institute of Hematology, Bologna, Italy, from 1980 to 2015. Overall 397 @entity0 (71%) required front-line corticosteroids, mainly @entity1 . Over the decades, splenectomy was delayed from second to third-line, but was steadily used in around 15-25% of @entity0 refractory or relapsing after first-line treatment. Consensually, RTX and @entity5 agonists emerged as second and third-line therapy of choice, respectively. Splenectomy was associated with the best response rates and the lower incidences of relapse, while the relapse rate after RTX was comparable to that observed with @entity2 and other immunosuppressive agents. The introduction of @entity5 agonists gave an alternative to the administration of immunosuppressive drugs and probably contributed to moderate the incidence of infectious complications that remained stable over the decades, despite an increasing use of RTX from the 2000s onwards. Overall responses were similar over time, with over 97% achieving a response in all time-periods. However, the cumulative risk of @entity3 significantly decreased (14.3% [1980-89] versus 7% [1990-99] versus 5.6% [2000-09] versus 0.2% [2010-15]) (p<0.001), mainly thanks to the optimization of front-line corticosteroids therapy and to the wider availability of second and third-line therapies. This article is protected by copyright. All rights reserved.

title: Have splenectomy rate and main outcomes of XXXX changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.

answer: @entity4


abstract: INTRODUCTION: The diagnosis of @entity2 based on the ECG is hampered by the dynamic nature of its ECG manifestations. @entity2 @entity0 are only 25% likely to present a type 1 ECG. The objective of this study is to provide an ECG diagnostic criterion for @entity2 @entity0 that can be applied consistently even in the absence of a type 1 ECG. METHODS AND RESULTS: We recorded 67-lead body surface potential maps from 94 @entity2 @entity0 and 82 controls (including @entity1 @entity0 and healthy individuals). The spatial propagation direction during the last r' wave and the slope at the end of the QRS complex were measured and compared between @entity0 groups. Receiver-operating characteristic curves were constructed for half of the database to identify optimal cutoff values; sensitivity and specificity for these cutoff values were measured in the other half of the database. A spontaneous type 1 ECG was present in only 30% of @entity3 @entity0 . An orientation in the sagittal plane<101   during the last r' wave and a descending slope<9.65mV/s enables the diagnosis of the syndrome with a sensitivity of 69% and a specificity of 97% in non-type 1 @entity2 @entity0 . CONCLUSION: Spatiotemporal characteristics of surface ECG recordings can enable a robust identification of @entity3 even without the presence of a type 1 ECG. This article is protected by copyright. All rights reserved.

title: Spatiotemporal Characteristics of QRS Complexes Enable the Diagnosis of XXXX Regardless of the Appearance of a Type 1 ECG.

answer: @entity2


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity1 in @entity0 and can cause insulin resistance in male @entity2 . @entity6 ( @entity10 )- @entity7 (SIR) immunosuppression is also associated with appearance of @entity3 in transplant @entity0 . Because insulin resistance is observed in @entity0 with @entity8 , we hypothesized that @entity10 or SIR may induce @entity5 . METHODS: We monitored estrus cycles of adult female @entity2 treated daily with @entity10 , SIR, and combination of @entity10 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity4 to determine their @entity4 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity10 and @entity10 -SIR treatments increased mean random @entity4 concentrations (P<0.05). @entity10 , SIR, and @entity10 -SIR treatments also increased the @entity4 response to oral @entity4 challenge (P<0.05). The insulin response to @entity4 was significantly higher in @entity2 treated with SIR compared with @entity10 (P<0.05). @entity10 , SIR and @entity10 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity10 -SIR treatment compared with controls. The @entity10 and @entity10 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity10 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity9 , both @entity10 and SIR induced @entity5 in adult female @entity2 , likely through different mechanisms.

title: @entity6 and @entity7 induce XXXX in female @entity2 .

answer: @entity5


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity1 in @entity0 and can cause insulin resistance in male @entity2 . @entity6 ( @entity10 )- @entity7 (SIR) immunosuppression is also associated with appearance of @entity3 in transplant @entity0 . Because insulin resistance is observed in @entity0 with @entity8 , we hypothesized that @entity10 or SIR may induce @entity5 . METHODS: We monitored estrus cycles of adult female @entity2 treated daily with @entity10 , SIR, and combination of @entity10 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity4 to determine their @entity4 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity10 and @entity10 -SIR treatments increased mean random @entity4 concentrations (P<0.05). @entity10 , SIR, and @entity10 -SIR treatments also increased the @entity4 response to oral @entity4 challenge (P<0.05). The insulin response to @entity4 was significantly higher in @entity2 treated with SIR compared with @entity10 (P<0.05). @entity10 , SIR and @entity10 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity10 -SIR treatment compared with controls. The @entity10 and @entity10 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity10 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity9 , both @entity10 and SIR induced @entity5 in adult female @entity2 , likely through different mechanisms.

title: @entity6 and XXXX induce @entity5 in female @entity2 .

answer: @entity7


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity1 in @entity0 and can cause insulin resistance in male @entity2 . @entity6 ( @entity10 )- @entity7 (SIR) immunosuppression is also associated with appearance of @entity3 in transplant @entity0 . Because insulin resistance is observed in @entity0 with @entity8 , we hypothesized that @entity10 or SIR may induce @entity5 . METHODS: We monitored estrus cycles of adult female @entity2 treated daily with @entity10 , SIR, and combination of @entity10 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity4 to determine their @entity4 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity10 and @entity10 -SIR treatments increased mean random @entity4 concentrations (P<0.05). @entity10 , SIR, and @entity10 -SIR treatments also increased the @entity4 response to oral @entity4 challenge (P<0.05). The insulin response to @entity4 was significantly higher in @entity2 treated with SIR compared with @entity10 (P<0.05). @entity10 , SIR and @entity10 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity10 -SIR treatment compared with controls. The @entity10 and @entity10 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity10 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity9 , both @entity10 and SIR induced @entity5 in adult female @entity2 , likely through different mechanisms.

title: XXXX and @entity7 induce @entity5 in female @entity2 .

answer: @entity6


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity1 in @entity0 and can cause insulin resistance in male @entity2 . @entity6 ( @entity10 )- @entity7 (SIR) immunosuppression is also associated with appearance of @entity3 in transplant @entity0 . Because insulin resistance is observed in @entity0 with @entity8 , we hypothesized that @entity10 or SIR may induce @entity5 . METHODS: We monitored estrus cycles of adult female @entity2 treated daily with @entity10 , SIR, and combination of @entity10 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity4 to determine their @entity4 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity10 and @entity10 -SIR treatments increased mean random @entity4 concentrations (P<0.05). @entity10 , SIR, and @entity10 -SIR treatments also increased the @entity4 response to oral @entity4 challenge (P<0.05). The insulin response to @entity4 was significantly higher in @entity2 treated with SIR compared with @entity10 (P<0.05). @entity10 , SIR and @entity10 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity10 -SIR treatment compared with controls. The @entity10 and @entity10 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity10 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity9 , both @entity10 and SIR induced @entity5 in adult female @entity2 , likely through different mechanisms.

title: @entity6 and @entity7 induce @entity5 in female XXXX .

answer: @entity2


abstract: INTRODUCTION: The @entity6 pain is common after a @entity1 . Its appearance brings @entity3 and limits daily living activities as well as participation in specific Neuro-rehabilitation programs. All this leads to a worse functional outcome. Good management of @entity0 can reduce both the frequency and intensity of @entity3 , improving functional outcome. DEVELOPMENT: We conducted a literature search of various databases between 1980 and 2008. The articles were evaluated using the PEDro scoring system. Five evidence levels were established for the conclusions. CONCLUSIONS: Shoulder subluxation, occurs at an early stage after @entity1 and is associated with subluxation of the shoulder joint and @entity5 (mainly subscapularis and pectoralis). Slings prevent subluxation of the shoulder. It is preferable to move within a lower range of motion and without @entity2 to prevent the occurrence of @entity3 . The injection of @entity4 does not improve @entity3 and range of motion in hemiplegic @entity0 , while botulinum toxin combined with physical therapy appears to reduce @entity6 pain.

title: [Painful @entity6 in XXXX @entity0 : causes and management].

answer: @entity1


abstract: INTRODUCTION: The @entity6 pain is common after a @entity1 . Its appearance brings @entity3 and limits daily living activities as well as participation in specific Neuro-rehabilitation programs. All this leads to a worse functional outcome. Good management of @entity0 can reduce both the frequency and intensity of @entity3 , improving functional outcome. DEVELOPMENT: We conducted a literature search of various databases between 1980 and 2008. The articles were evaluated using the PEDro scoring system. Five evidence levels were established for the conclusions. CONCLUSIONS: Shoulder subluxation, occurs at an early stage after @entity1 and is associated with subluxation of the shoulder joint and @entity5 (mainly subscapularis and pectoralis). Slings prevent subluxation of the shoulder. It is preferable to move within a lower range of motion and without @entity2 to prevent the occurrence of @entity3 . The injection of @entity4 does not improve @entity3 and range of motion in hemiplegic @entity0 , while botulinum toxin combined with physical therapy appears to reduce @entity6 pain.

title: [Painful XXXX in @entity1 @entity0 : causes and management].

answer: @entity6


abstract: INTRODUCTION: The @entity6 pain is common after a @entity1 . Its appearance brings @entity3 and limits daily living activities as well as participation in specific Neuro-rehabilitation programs. All this leads to a worse functional outcome. Good management of @entity0 can reduce both the frequency and intensity of @entity3 , improving functional outcome. DEVELOPMENT: We conducted a literature search of various databases between 1980 and 2008. The articles were evaluated using the PEDro scoring system. Five evidence levels were established for the conclusions. CONCLUSIONS: Shoulder subluxation, occurs at an early stage after @entity1 and is associated with subluxation of the shoulder joint and @entity5 (mainly subscapularis and pectoralis). Slings prevent subluxation of the shoulder. It is preferable to move within a lower range of motion and without @entity2 to prevent the occurrence of @entity3 . The injection of @entity4 does not improve @entity3 and range of motion in hemiplegic @entity0 , while botulinum toxin combined with physical therapy appears to reduce @entity6 pain.

title: [Painful @entity6 in @entity1 XXXX : causes and management].

answer: @entity0


abstract: Stigma associated with @entity2 ( @entity2 ) is often regarded as a barrier to health seeking and a cause of social suffering. Stigma studies are typically @entity0 -centred, and less is known about the views of communities where @entity0 reside. This study examined community perceptions of @entity2 . A total of 160 respondents (80 @entity0 and 80 @entity0 ) without @entity2 in the general population of Western Maharashtra, India, were interviewed using Explanatory Model Interview Catalogue interviews with same-sex and cross-sex vignettes depicting a @entity0 with typical features of @entity2 . The study clarified features of @entity2 . Concealment of disease was explained as fear of losing social status, marital problems and hurtful behaviour by the community. For the female vignette, heredity was perceived as a cause for stigmatising behaviour. Marital problems were anticipated more for the male vignette. Anticipation of spouse support, however, was more definite for @entity0 and conditional for @entity0 , indicating the vulnerability of @entity0 . Community views acknowledged that both @entity0 and @entity0 with @entity2 share a psychological burden of unfulfilled social responsibilities. The distinction between public health risks of @entity1 and unjustified social isolation (stigma) was ambiguous. Such a distinction is important for effective community-based interventions for early diagnosis of @entity2 and successful treatment.

title: Gender and community views of stigma and XXXX , India.

answer: @entity2


abstract: Spinal cord (SC) @entity2 , i.e. a reduction in the SC cross-sectional area (CSA) over time, can be measured by means of image segmentation using magnetic resonance imaging (MRI). However, segmentation methods have been limited by factors relating to reproducibility or sensitivity to change. The purpose of this study was to evaluate a fully automated SC segmentation method (PropSeg), and compare this to a semi-automated @entity5 ( @entity5 ) method, in healthy controls (HC) and @entity0 with @entity1 ( @entity1 ). MRI data from 120 @entity0 were retrospectively analysed; 26 HC, 21 with @entity4 , 26 relapsing remitting @entity1 , 26 primary and 21 secondary progressive @entity1 . MRI data from 40 @entity0 returning after one year were also analysed. CSA measurements were obtained within the cervical SC. Reproducibility of the measurements was assessed using the intraclass correlation coefficient (ICC). A comparison between mean CSA changes obtained with the two methods over time was performed using multivariate structural equation regression models. Associations between CSA measures and clinical scores were investigated using linear regression models. Compared to the @entity5 method, the reproducibility of CSA measurements obtained with PropSeg was high, both in @entity0 and in HC, with ICC  >  0.98 in all cases. There was no significant difference between PropSeg and @entity5 in terms of detecting change over time. Furthermore, PropSeg provided measures that correlated with @entity3 , similar to the @entity5 method. PropSeg is a time-efficient and reliable segmentation method, which requires no manual intervention, and may facilitate large multi-centre neuroprotective trials in progressive @entity1 .

title: Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to XXXX .

answer: @entity1


abstract: Clinical decision support (CDS) systems show promise for enhancing @entity0 safety, but they require rigorous evaluation before they can be implemented widely. We developed a software application for use with personal digital assistants (PDAs) that models @entity0 -specific dose responses to help physicians predict steady-state @entity1 dosing requirements and steer @entity0 to a therapeutic level of anticoagulation as quickly and safely as possible. We also designed a randomized, controlled multi-site trial to evaluate the effectiveness of the @entity1 Dosing and Communication System (WARFDOCS) in reducing @entity1 -related errors. Numerous obstacles delayed implementation of the CDS system and completion of the trial. To better understand the causes that led to the delay, we interviewed key informants at participating hospitals; reviewed study protocols, administrative records, and meeting minutes; and held discussions to review the data and their interpretation. Salient themes were identified by consensus of the research team and these were corroborated by key informants. Four major themes emerged. First, agreement to participate in the trial reflected very different levels of commitment. Sites participating in CDS system evaluations must be managed actively. Second, the enthusiasm of end-users for a CDS system was derived from a complex calculus of perceived benefits and burdens. Unfortunately, the most relevant appeal (that such a system would markedly improve @entity0 safety) could not be made in advance of the trial. Third, research changes everything. Valid research procedures (e.g., informed consent, randomization, and intrusive data collection) may be necessary, but can themselves affect a key outcome of most CDS system evaluations: user uptake. Fourth, strong    center effects    (i.e., the CDS system proved effective at some sites, but not at others) should be expected. If    all politics is local,    then much of @entity0 safety research is localized as well.

title: From Insight to Implementation: Lessons from a Multi-site Trial of a PDA-based XXXX Dose Calculator

answer: @entity1


abstract: BACKGROUND AND STUDY AIMS: Endoscopic submucosal dissection (ESD) is a standard treatment for early @entity3 (EGC) without lymph node @entity1 . However, some @entity0 undergo noncurative ESD. The aim of the present study was to assess the long-term clinical outcomes of noncurative ESD with or without additional surgery. @entity0 AND METHODS: We investigated the chart data from all @entity0 who had undergone ESD for EGC at Saga Medical School Hospital and Saga Prefectural Medical Centre Koseikan between 2001 and 2012. A total of 957 cases (1047 lesions) of EGC underwent ESD, and 99 had noncurative ESD. In total, 20 cases were excluded because their follow-up period was <3 years. We divided the @entity0 into observation and additional surgery groups, and we compared the survival rate and related factors between the groups. RESULTS: After noncurative ESD, 28/79 @entity0 (35.4%) underwent additional surgery and 51/79 (64.6%) were followed up without surgery. The average age of @entity0 in the observation group was higher than that of the additional surgery group (75.9 vs. 71.6 years; P=0.03). The incidence of @entity2 was significantly higher in the observation group compared with the additional surgery group (51.0 vs. 25.9%; P=0.03). The overall survival rate of the additional surgery group was longer than that of the observation group.However, only one @entity0 died from @entity3 in the observation group.The disease-specific survival rate did not differ significantly between the groups. CONCLUSIONS: It might be acceptable to follow up without additional surgery for some @entity0 with comorbidity and who were elderly after noncurative ESD for EGC.

title: Effect of additional surgery after noncurative endoscopic submucosal dissection for early XXXX .

answer: @entity3


abstract: BACKGROUND AND STUDY AIMS: The treatment success of @entity1 with fully covered metal stents (CSEMS) is altered by high stent dislocation rates. We aimed to evaluate a new stent design to prevent dislocation. @entity0 AND METHODS: @entity0 with @entity1 were treated with a newly designed double-coned stent (dcSEMS). Mechanical analysis of the new stent was performed and it was compared with a cylindrical stent. RESULTS: A total of 13 dcCSEMS were implanted in 11 @entity0 (2 female, 9 male, median age 47, range 33-71). All @entity0 had @entity1 due to chronic @entity4 . No stent migration occurred. In all but one @entity0 the stents were removed. One @entity0 refused stent extraction and was lost to follow up. @entity3 occurred twice leading to @entity2 in both cases. The duration of stent treatment was 170 days (range 61-254). After extraction only one @entity0 had early recurrent stricture and received the same stent again. Three stents showed minimal tissue granulation at the papilla. One stent presented ingrowth at the proximal end and was removed after implantation of a second fully covered stent. Mechanical examination revealed significantly lower radial expansion force of the new stent as compared to the cylindrical stent. CONCLUSIONS: The new stent design has a low rate of migration. Biomechanical properties may explain this effect.

title: Anatomy-shaped design of a fully-covered, biliary, self-expandable metal stent for treatment of benign XXXX .

answer: @entity1


abstract: AIM: An association between body mass index (BMI) and @entity2 outcome have been reported, but the results are controversial. The aim of the present study was to evaluate whether BMI is associated with @entity3 outcome. METHODS: Consecutive Japanese acute @entity3 @entity0 were analyzed. BMI was categorized as underweight (BMI <18.5   kg/m(2) ), normal weight (18.5-24.9   kg/m(2) ) and @entity1 (>= 25   kg/m(2) ). BMI and short-term and long-term outcomes were examined. Short-term outcomes were evaluated using the modified Rankin scale score at hospitalization and discharge; modified Rankin scale >= 3 was defined as a poor outcome. Long-term outcomes were evaluated by all-cause mortality. The recurrence rate was also evaluated in each BMI group. Values of P   <   0.05 were considered significant. RESULTS: A total of 1206 acute @entity3 @entity0 (760 @entity0 ; mean age 72.5 years) were analyzed in the present study. There were 111 underweight cases (9.2%), 785 normal weight cases (65.1%) and 310 @entity1 cases (25.7%). The underweight group had a significantly higher rate of poor short and long-term outcomes than the normal weight group. The outcomes of the @entity1 group were not significantly different from those of the normal weight group. Recurrence was not significantly different among the groups. CONCLUSIONS: Lower BMI might be a predictor of poorer short-term and long-term @entity2 outcomes. Geriatr Gerontol Int 2016;       :       -      .

title: Association between body mass index and outcome in Japanese XXXX @entity0 .

answer: @entity3


abstract: AIM: An association between body mass index (BMI) and @entity2 outcome have been reported, but the results are controversial. The aim of the present study was to evaluate whether BMI is associated with @entity3 outcome. METHODS: Consecutive Japanese acute @entity3 @entity0 were analyzed. BMI was categorized as underweight (BMI <18.5   kg/m(2) ), normal weight (18.5-24.9   kg/m(2) ) and @entity1 (>= 25   kg/m(2) ). BMI and short-term and long-term outcomes were examined. Short-term outcomes were evaluated using the modified Rankin scale score at hospitalization and discharge; modified Rankin scale >= 3 was defined as a poor outcome. Long-term outcomes were evaluated by all-cause mortality. The recurrence rate was also evaluated in each BMI group. Values of P   <   0.05 were considered significant. RESULTS: A total of 1206 acute @entity3 @entity0 (760 @entity0 ; mean age 72.5 years) were analyzed in the present study. There were 111 underweight cases (9.2%), 785 normal weight cases (65.1%) and 310 @entity1 cases (25.7%). The underweight group had a significantly higher rate of poor short and long-term outcomes than the normal weight group. The outcomes of the @entity1 group were not significantly different from those of the normal weight group. Recurrence was not significantly different among the groups. CONCLUSIONS: Lower BMI might be a predictor of poorer short-term and long-term @entity2 outcomes. Geriatr Gerontol Int 2016;       :       -      .

title: Association between body mass index and outcome in Japanese @entity3 XXXX .

answer: @entity0


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity4 determinants, CCDs) may induce double IgE reactivity to @entity5 venom ( @entity2 ) and yellow jacket venom (YJV) in @entity0 who are monosensitized to either of these venoms. @entity3 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity2 and YJV) IgE reactivity in @entity0 who are @entity1 to Hymenoptera venom, and in particular, @entity3 consumption. METHODS: Ninety-one @entity0 with Hymenoptera allergy (68 to @entity2 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity2 , YJV, natural (glycosylated) @entity2 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity2 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity2 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity0 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity3 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5 and @entity6 ) IgE reactivity are common among Hymenoptera venom- @entity1 @entity0 who drink @entity3 . A simple questionnaire about @entity3 consumption could be useful when interpreting levels of specific IgE in these @entity0 .

title: Double ( @entity5 and @entity6 ) immunoglobulin E reactivity in @entity0 XXXX to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity3 consumption.

answer: @entity1


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity4 determinants, CCDs) may induce double IgE reactivity to @entity5 venom ( @entity2 ) and yellow jacket venom (YJV) in @entity0 who are monosensitized to either of these venoms. @entity3 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity2 and YJV) IgE reactivity in @entity0 who are @entity1 to Hymenoptera venom, and in particular, @entity3 consumption. METHODS: Ninety-one @entity0 with Hymenoptera allergy (68 to @entity2 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity2 , YJV, natural (glycosylated) @entity2 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity2 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity2 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity0 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity3 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5 and @entity6 ) IgE reactivity are common among Hymenoptera venom- @entity1 @entity0 who drink @entity3 . A simple questionnaire about @entity3 consumption could be useful when interpreting levels of specific IgE in these @entity0 .

title: Double ( XXXX and @entity6 ) immunoglobulin E reactivity in @entity0 @entity1 to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity3 consumption.

answer: @entity5


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity4 determinants, CCDs) may induce double IgE reactivity to @entity5 venom ( @entity2 ) and yellow jacket venom (YJV) in @entity0 who are monosensitized to either of these venoms. @entity3 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity2 and YJV) IgE reactivity in @entity0 who are @entity1 to Hymenoptera venom, and in particular, @entity3 consumption. METHODS: Ninety-one @entity0 with Hymenoptera allergy (68 to @entity2 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity2 , YJV, natural (glycosylated) @entity2 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity2 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity2 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity0 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity3 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5 and @entity6 ) IgE reactivity are common among Hymenoptera venom- @entity1 @entity0 who drink @entity3 . A simple questionnaire about @entity3 consumption could be useful when interpreting levels of specific IgE in these @entity0 .

title: Double ( @entity5 and @entity6 ) immunoglobulin E reactivity in @entity0 @entity1 to Hymenoptera venom: the role of cross-reactive carbohydrates and XXXX consumption.

answer: @entity3


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity4 determinants, CCDs) may induce double IgE reactivity to @entity5 venom ( @entity2 ) and yellow jacket venom (YJV) in @entity0 who are monosensitized to either of these venoms. @entity3 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity2 and YJV) IgE reactivity in @entity0 who are @entity1 to Hymenoptera venom, and in particular, @entity3 consumption. METHODS: Ninety-one @entity0 with Hymenoptera allergy (68 to @entity2 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity2 , YJV, natural (glycosylated) @entity2 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity2 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity2 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity0 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity3 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5 and @entity6 ) IgE reactivity are common among Hymenoptera venom- @entity1 @entity0 who drink @entity3 . A simple questionnaire about @entity3 consumption could be useful when interpreting levels of specific IgE in these @entity0 .

title: Double ( @entity5 and XXXX ) immunoglobulin E reactivity in @entity0 @entity1 to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity3 consumption.

answer: @entity6


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity4 determinants, CCDs) may induce double IgE reactivity to @entity5 venom ( @entity2 ) and yellow jacket venom (YJV) in @entity0 who are monosensitized to either of these venoms. @entity3 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity2 and YJV) IgE reactivity in @entity0 who are @entity1 to Hymenoptera venom, and in particular, @entity3 consumption. METHODS: Ninety-one @entity0 with Hymenoptera allergy (68 to @entity2 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity2 , YJV, natural (glycosylated) @entity2 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity2 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity2 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity0 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity3 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5 and @entity6 ) IgE reactivity are common among Hymenoptera venom- @entity1 @entity0 who drink @entity3 . A simple questionnaire about @entity3 consumption could be useful when interpreting levels of specific IgE in these @entity0 .

title: Double ( @entity5 and @entity6 ) immunoglobulin E reactivity in XXXX @entity1 to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity3 consumption.

answer: @entity0


abstract: Late @entity5 enhancement (LGE) is widely used to precisely localize and determine the extent and transmurality of @entity3 . Performing LGE imaging at end-systole may reduce motion artefacts. It is therefore important to know whether end-systolic imaging influences infarct transmurality in @entity0 with @entity1 . 107 dysfunctional segments were studied in 20 consecutive @entity0 with established @entity4 . @entity0 specific trigger delays were used to obtain end-diastolic and end-systolic LGE images (LGE(ed), LGE(es)). Wall thickness ( @entity6 (ed), @entity6 (es)), thickness of the remaining viable rim (RIM(ed), RIM(es)) and end-diastolic scar thickness were measured manually. There was LGE in 84% of all dysfunctional segments with a mean scar of 3.4    2.5 mm. Total wall thickness and the thickness of the remaining viable rim increased from diastole to systole ( @entity6 (ed) 7.8    1.9 vs. @entity6 (es) 8.4    2.2; P < 0.001; RIM(ed) 4.4    3.1 vs. RIM(es) 5    3.4; P < 0.001). Transmurality of scar decreased from end-diastole to end-systole (LGE(ed) 46    33% vs. LGE(es) 44    33%; P < 0.001). This was most pronounced in a subgroup of segments (n = 15) with @entity2 between 50 and 75% (LGE(ed) 75    15% vs. LGE(es) 70    16%; P < 0.001). The change in transmurality was inversely correlated with the change of the thickness of the remaining viable rim between diastole and systole (r = -0.7; P < 0.001). Scar transmurality was reduced by up to 12% in the individual @entity0 . Scar transmurality changes due to thickening of the remaining viable rim. Whereas these differences might not impact on clinical decision-making in most @entity0 , there will be an occasional misclassification if cut-off values are used (e.g. scar <50 or >50%) or if exact data is required for research studies.

title: End-systolic versus end-diastolic late XXXX enhanced imaging for the assessment of scar transmurality.

answer: @entity5


abstract: BACKGROUND AND PURPOSE: To compare psychosocial burden in @entity0 with essential @entity4 (ET) in an outpatient (OPC)- and a community-based cohort (CBC). METHODS: A sample of outpatients of a tertiary referral center (n = 180) and a community-based sample (n = 100) with ET were asked for study participation. Psychosocial aspects were assessed by a questionnaire on psychosocial aspects of ET, neuropsychological scales, quality of life, personality traits, and coping strategies. RESULTS: One hundred and seven @entity0 of the OPC and 90 individuals of the CBC participated and their results are descriptively presented. Statistical analysis was restricted to 38 pairs of OPC and CBC individuals matched for age, sex, and @entity4 severity. One-third of these individuals reported a profound impairment in everyday or professional life. Neuropsychological scales showed a severe @entity3 in 8% of the individuals and pathologic values for the general level of @entity2 symptoms in 26%. The main coping strategy was 'active problem-orientated coping'. @entity0 of the OPC perceived a more severe impact of ET on their life. Multivariate analysis revealed the Beck Depression Inventory score as the only predictive factor for the outcome variables, physical and mental component scores, of the SF-12 health survey. CONCLUSIONS: ET causes a significant @entity1 , which does depend on symptom severity but also on mood with @entity3 as the main driving factor and other so far undetermined factors.

title: The psychosocial burden of essential XXXX in an outpatient- and a community-based cohort.

answer: @entity4


abstract: AIM: To estimate the late duration of the effect of 3-week intravenous @entity4 (alpha-LA) administration. SUBJECTS AND METHODS: The study included @entity0 with symptoms of @entity2 . The authors studied trends in @entity3 by the TSS scale and @entity1 by the NIS-LL scale after 3-week intravenous alpha-LA (600 mg/day) administration. Control follow-up visits were made at weeks 8 and 30 of the study. RESULTS: In alpha-LA-treated @entity0 , the mean TSS score dropped from 9.46 +/- 1.01 to 3.29 +/- 1.49 after intravenous alpha-LA administration and continued to decrease to 260 +/- 1.18 and 4.39 +/- 201 scores at follow-up weeks 8 and 30, respectively. In the placebo group, these were 9.78 +/- 1.23, 6.16 +/- 1.95, 6.52 +/- 1.61, and 736 +/- 1.31 scores at weeks 3, 8, and 30, respectively; p < 0.05). In the alpha-LA group, NIS-LL scores fell from 8.65 +/- 3.46 to 6.01 +/- 3.12 at therapy week 3, to 6.11 +/- 3.36, at week 8, and to 7.68 +/- 3.68 at week 30 and in the placebo group, these decreased from 8.35 +/- 3.84 to 7.81 +/- 3.51, 7.89 +/- 3.72, and 8.32 +/- 3.49 scores at weeks 3, and 8, respectively; p < 0.05). CONCLUSION: . Alleviated @entity3 persisted within 6 months after 3-week intravenous alpha-LA injection. Reduced @entity1 did within 8 weeks after initiation of alpha-LA therapy.

title: [Long-term effect of 3-week intravenous XXXX administration in symptomatic diabetic polyneutropathy with clinical manifestations].

answer: @entity4


abstract: BACKGROUND: Modification of allergens by @entity4 in extracts used for immunotherapy reduces the risk for side effects, but therapeutic efficacy of such extracts requires further evaluation. The aim of this study was to evaluate the efficacy and safety of immunotherapy with PURETHAL Mites (PM), a single-strength @entity4 -modified @entity8 -adsorbed extract of @entity5 ( @entity5 ). METHODS: In a multicenter, randomized, placebo-controlled double-blind setting, @entity5 -allergic subjects (n = 140) were treated with modified allergen extract or placebo over a 1-year period. The primary outcome parameter was a combined symptom and medication score (clinical index score [CIS]). Secondary efficacy parameters were the result of a titrated conjunctival provocation test (CPT), @entity3 / @entity7 quality of life (RQL) score, and serum concentrations of IgE and IgG against specific @entity5 allergens and a documentation of adverse events (AE). RESULTS: We evaluated 140 @entity0 (66 treatment and 74 placebo) for clinical efficacy. The allergoid treatment for 1 year resulted in significantly greater CIS improvement and higher RQL scores. The response threshold in the titrated @entity1 (p = 0.009) and the serum concentrations of IgG4 (p < 0.001) against @entity6 allergens after treatment were also significantly different between groups. In total, 88 @entity0 (46 PM/42 placebo) out of a safety population of 145 reported 278 (158 PM/120 placebo) AE. Except for local reactions, no specific AE appeared to be associated with PURETHAL Mites (HAL-Allergy, Leiden, The Netherlands). CONCLUSION: The findings of this study indicate that allergen injection therapy with modified @entity5 extract is superior to placebo in @entity2 therapy. The treatment was well tolerated and no serious drug-related AE were observed.

title: Efficacy and safety of a XXXX -modified house dust mite extract in @entity2 .

answer: @entity4


abstract: BACKGROUND: Modification of allergens by @entity4 in extracts used for immunotherapy reduces the risk for side effects, but therapeutic efficacy of such extracts requires further evaluation. The aim of this study was to evaluate the efficacy and safety of immunotherapy with PURETHAL Mites (PM), a single-strength @entity4 -modified @entity8 -adsorbed extract of @entity5 ( @entity5 ). METHODS: In a multicenter, randomized, placebo-controlled double-blind setting, @entity5 -allergic subjects (n = 140) were treated with modified allergen extract or placebo over a 1-year period. The primary outcome parameter was a combined symptom and medication score (clinical index score [CIS]). Secondary efficacy parameters were the result of a titrated conjunctival provocation test (CPT), @entity3 / @entity7 quality of life (RQL) score, and serum concentrations of IgE and IgG against specific @entity5 allergens and a documentation of adverse events (AE). RESULTS: We evaluated 140 @entity0 (66 treatment and 74 placebo) for clinical efficacy. The allergoid treatment for 1 year resulted in significantly greater CIS improvement and higher RQL scores. The response threshold in the titrated @entity1 (p = 0.009) and the serum concentrations of IgG4 (p < 0.001) against @entity6 allergens after treatment were also significantly different between groups. In total, 88 @entity0 (46 PM/42 placebo) out of a safety population of 145 reported 278 (158 PM/120 placebo) AE. Except for local reactions, no specific AE appeared to be associated with PURETHAL Mites (HAL-Allergy, Leiden, The Netherlands). CONCLUSION: The findings of this study indicate that allergen injection therapy with modified @entity5 extract is superior to placebo in @entity2 therapy. The treatment was well tolerated and no serious drug-related AE were observed.

title: Efficacy and safety of a @entity4 -modified house dust mite extract in XXXX .

answer: @entity2


abstract: BACKGROUND: Great variability in @entity0 ( @entity0 ) treatment practices according to @entity1 , @entity2 or organisation of care characteristics has been reported but the relation between these factors is not well known. In two French regions, we measured compliance with Clinical Practice Guidelines for non-metastatic @entity0 care management and identified factors associated with non-compliance at clinical and organisational levels. METHODS: Eligible @entity1 had invasive unilateral @entity0 without distant metastases and at least two contacts with one of the two regional healthcare systems (2003-2004) in the first year after diagnosis. Medical data were collected from @entity1 medical records in all public and private hospitals (99 hospitals).The care process was defined by 20 criteria: clinical decisions for treatment and therapeutic procedures. Each criterion was classified according to level of compliance ("Compliant", "Justifiable" and "Not Compliant") and factors of non-compliance were identified (mixed effect logistic regression). RESULTS: 926 @entity1 were included. Non-compliance with clinical decisions for treatment was associated with older @entity1 age (OR 2.1; 95%CI: 1.3-3.6) and region (OR 3.0; 95%CI: 1.2-7.4). Non-compliance with clinical decisions for radiotherapy was associated with lymph node involvement or the presence of peritumoural vascular invasion (OR 1.5; 95%CI: 1.01-2.3) and non-compliance with overall treatment (clinical decisions for treatment + therapeutic procedures) was associated with the presence of positive lymph nodes (OR 2.0; 95%CI: 1.2-3.3), grade III versus grade I (OR 2.9; 95%CI: 1.4-6.2), and one region of care versus another (OR 3.5; 95%CI: 1.7-7.1). Finally, heterogeneity of compliance in overall treatment sequence was identified between @entity2 units (p < 0.05). CONCLUSION: This study provides interesting insights into factors of non-compliance in non-metastatic @entity0 management and could lead to quality care improvements.

title: XXXX care compared with clinical Guidelines: an observational study in France.

answer: @entity0


abstract: INTRODUCTION: Cardiac @entity2 are found in six to 20% of autopsies of @entity1 with @entity3 . The most common @entity3 that metastasize to the heart are @entity5 , and @entity6 , but the relative numbers are greater with @entity0 , reflecting the most common incidence of these @entity3 . CASE PRESENTATION: A 60-year-old Hispanic @entity1 presented to our hospital after being transferred from an outside hospital for workup and evaluation of an adrenal mass of the abdomen and pelvis, found on computed tomography. His chief complaint upon admission was altered mental status. Physical examination was unremarkable. He was alert and oriented and had a dry and non-erythematous oropharynx, and bilateral diffuse wheezing on lung examination. Computed tomography of the chest showed @entity4 in the left ventricular myocardium, suggestive of @entity2 . There were also tiny sub-centimeter nodular densities in the right upper and lower lobes. Adrenal glands contained @entity4 , which showed characteristic adenocarcinomatous malignant cells. CONCLUSION: @entity3 which have metastasized to the heart are found in six to 20% of @entity1 with @entity3 . The right side of the heart is more commonly involved in @entity2 . This study is unusual in that a @entity3 of an unknown primary origin had metastasized to the left side of the heart.

title: An unusual case of XXXX to the left side of the heart: a case report.

answer: @entity2


abstract: Previous studies have demonstrated a correlation between E:E(a) and ventricular filling pressure in adults after heart transplantation. We sought to determine if E:E(a) correlates with filling pressure after heart transplantation in chil @entity0 prospective analysis of chil @entity0 have undergone heart transplantation was performed. Inflow and myocardial velocities were recorded and compared to catheter-derived filling pressures and rejection status. We performed 61 studies in 49 subjects. No correlation was found between septal E:E(a) and PCWP (r=0.14, p=0.28); or between lateral tricuspid E:E(a) and mean RAp @entity1 0.04, p=0.79). However, the mean PCWP was higher among subjects with elevated septal E:E(a) (>12) compared to normal E:E(a) (12.3  2.8mmHg vs. 10.1  2.9mmHg, p=0.02). Similarly, mean RAp @entity1 higher among subjects with an elevated lateral tricuspid E:E(a) (>10) compared to normal lateral tricuspid E:E(a) (7.7  2.1mmHg vs. 6.0  2.4mmHg, p=0.04). Elevated septal E:E(a) was also associated with high-grade cellular rejection (OR=17.3 [95% CI 1.4-221], p=0.028). In chil @entity0 lowing heart transplant, E:E(a) does not correlate well with the range of filling pressures seen after pediatric heart transplantation. However, a septal E:E(a)>12 is associated with elevated PCWP and high grade cellular rejection and a lateral tricuspid E:E(a)>10 is associated with elevated mean RAp. @entity1

title: Doppler tissue imaging in XXXX following cardiac transplantation: a comparison to catheter derived hemodynamics.

answer: @entity0


abstract: We tested the acceptability of three new lipid-based nutrient supplements (LNSs) in two independent phases among 18 8-12-month-old healthy rural Malawians and their caregivers. In phase 1, acceptability was assessed by offering three new LNSs in random order, and an @entity2 already determined to be acceptable, Nutributter(  ), each added to 30 g of warm @entity1 porridge over three consecutive days. In phase 2, @entity0 from each village were provided one of the new supplements for a 2-week home-use trial. Outcome measures included the amount consumed, time completion of the dose and the maternal rating of likeability on a 5-point scale. The supplements were rated acceptable if consumption was over 50% of the offered dose in phase 1. The mean (95% confidence interval) proportion of the @entity2 test meals consumed under direct observation was 88% (82-94%) for @entity2 -10gM, 90% (84-95%) for @entity2 -20gM, 87% (79-95%) for @entity2 -20gNoM, and 86% (83-90%) for Nutributter. The median (25th and 75th centile) time (minutes) for completing the offered test meal was 4 (2, 7) for @entity2 -10gM, 5 (3, 6) for @entity2 -20gM, 4 (3, 8) for @entity2 -20gNoM and 4 (2, 6) for Nutributter. During both phases, almost all caregivers rated all study foods very likeable for themselves and their @entity0 , with mean scores slightly lower among the caregivers than among the @entity0 . In the home-use phase, the test foods were almost exclusively used by the study @entity0 with minimal sharing with siblings and other household members. Some @entity0 were reported to prefer the new investigational products over traditional complementary food. Considering that the novel @entity2 was largely acceptable. Efficacy trials are now needed to assess their impact on @entity0 growth and development.

title: Acceptability of three novel lipid-based nutrient supplements among Malawian XXXX and their caregivers.

answer: @entity0


abstract: AIM: The aim of the study was to evaluate the prevalence and risk factors of @entity1 among Polish adolescent @entity0 . MATERIAL AND METHODS: A total of 2500 females from the Upper Silesian region of Poland, aged 16 to 45 years, were eligible for a prospective population-based study. The subjects were recruited randomly by the regional public opinion research centre. The preliminary study population consisted of 1540 females. Seventy-two adolescent @entity0 , aged 16 to 19 years, were included in the final analysis. The research was based on a self-prepared questionnaire containing socio-economic status, general health, medical and reproductive history, @entity2 based on American College of Obstetricians and Gynecologists criteria for diagnosing @entity3 as well as American Psychiatric Association criteria for @entity4 and @entity0 prospective daily ratings of symptoms. RESULTS: The mean age of the studied population was 17.27  0.97 years. In the studied population the majority of the adolescent @entity0 lived in large cities of over 50,000 citizens (54.29%), were physically active declaring daily physical exercise (55.22%) and sexually active (54.17%). Study results indicated that the prevalence of @entity3 and @entity4 was 76.39% and 4.17%, respectively. The final statistical analysis revealed that only place of residence (large cities) increased the risk of @entity3 (OR=3.58; P=0.01). CONCLUSION: Adolescent females living in urban areas are more vulnerable to @entity3 . Reproductive, sexual and socio-economic factors are not significant risk factors for @entity3 .

title: XXXX in Polish adolescent @entity0 : prevalence and risk factors.

answer: @entity1